

*Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

## **Draft Guidance on Halobetasol Propionate**

**August 2024**

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

In general, FDA’s guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

---

<b>Active Ingredient:</b>	Halobetasol propionate
<b>Dosage Form:</b>	Ointment
<b>Route:</b>	Topical
<b>Strength:</b>	0.05%
<b>Recommended Studies:</b>	Two options: (1) two in vitro bioequivalence studies and other characterization tests, (2) one in vivo (vasoconstrictor) bioequivalence study with pharmacodynamic endpoint

### **I. Option 1: Two in vitro bioequivalence studies and other characterization tests**

To demonstrate bioequivalence for halobetasol propionate topical ointment, 0.05% using in vitro studies, the following criteria should be met:

1. The test product should contain no difference in inactive ingredients or in other aspects of the formulation relative to the reference standard (RS) that may significantly affect the local or systemic availability of the active ingredient. For example, if the test product and RS are qualitatively (Q1) and quantitatively (Q2) the same, as defined in the most recent version of the FDA guidance for industry on *ANDA Submissions – Refuse-to-Receive Standards*<sup>a</sup>, and the criteria below are also satisfied, the bioequivalence of the test product may be established using a characterization-based bioequivalence approach.
2. The test product and RS should have the same physicochemical and structural (Q3) attributes, based upon acceptable comparative Q3 characterization tests with a minimum of three batches of the test product and three batches (as available) of the RS. The test product and RS batches should ideally represent the product at different ages throughout

its shelf life. Refer to the most recent version of the FDA guidance for industry on *Physicochemical and Structural (Q3) Characterization of Topical Drug Products Submitted in ANDAs*<sup>a</sup> for additional information regarding comparative Q3 characterization tests. The comparison of the test product and RS should include characterizations of the following Q3 attributes:

- a. Characterization of visual appearance and texture
  - b. Characterization of phase states and structural organization of matter
    - Microscopic examination with representative high-resolution microscopic images at multiple magnifications
    - Analysis of globule size distribution
  - c. Characterization of rheological behavior which may be characterized using a rheometer that is appropriate for monitoring the non-Newtonian flow behavior of semi-solid dosage forms. The following evaluations are recommended:
    - A characterization of shear stress vs. shear rate and viscosity vs. shear rate. At minimum, this should consist of numerical viscosity data at three shear rates (low, medium, and high).
    - A complete flow curve across the range of attainable shear rates, until low or high shear plateaus are identified.
    - Yield stress values should be reported if the material tested exhibits plastic flow behavior.
    - The linear viscoelastic response (storage and loss modulus vs. frequency) should be measured and reported. Any non-linear viscosity behavior over a range of shear rates should also be investigated, measured and reported.
  - d. Characterization of oleaginous components
  - e. Characterization of specific gravity
  - f. Characterization of any other potentially relevant Q3 attributes
3. The test product and RS should have an equivalent rate of halobetasol propionate release based upon an acceptable in vitro release test (IVRT) bioequivalence study comparing a minimum of one batch each of the test product and RS using an appropriately validated IVRT method.

Type of study: Bioequivalence study with IVRT endpoint

Design: Single-dose, two-treatment, parallel, multiple-replicate per treatment group study design using an occluded pseudo-infinite dose, in vitro

Strength: 0.05%

Test system: A synthetic membrane in a diffusion cell system

Analyte to measure: Halobetasol propionate in receptor solution

Bioequivalence based on: Halobetasol propionate (IVRT endpoint: drug release rate)

Additional comments: Refer to the most recent version of the FDA guidance for industry on *In Vitro Release Test Studies for Topical Drug Products Submitted in ANDAs*<sup>a</sup> for additional information regarding the development, validation, conduct and analysis of acceptable IVRT methods/studies. The batches of test product and RS evaluated in the IVRT bioequivalence study should be included among those for which the Q3 attributes are characterized.

4. The test product and RS should have equivalent rate and extent of halobetasol propionate permeation through excised human skin based upon an acceptable in vitro permeation test (IVPT) bioequivalence study comparing a minimum of one batch each of the test product and RS using an appropriately validated IVPT method.

Type of study: Bioequivalence study with IVPT endpoints

Design: Single-dose, two-treatment, parallel, multiple-replicate per treatment group study design using an unoccluded finite dose, in vitro

Strength: 0.05%

Test system: Barrier-competent human skin from male and/or female donors of at least 18 years of age in a diffusion cell system

Analyte to measure: Halobetasol propionate in receptor solution

Bioequivalence based on: Halobetasol propionate (IVPT endpoints: total cumulative amount (AMT) and maximum flux ( $J_{max}$ ))

Additional comments: Refer to the most recent version of the FDA guidance for industry on *In Vitro Permeation Test Studies for Topical Drug Products Submitted in ANDAs*<sup>a</sup> for additional information regarding the development, validation, conduct and analysis of acceptable IVPT methods/studies. The batches of test product and RS evaluated in the IVPT bioequivalence study should be the same as those evaluated in the IVRT bioequivalence study.

## II. Option 2: One in vivo (vasoconstrictor) bioequivalence study with pharmacodynamic endpoint

1. A. Type of study: Pilot vasoconstrictor study  
Design: A pilot dose duration-response study using the RS  
Strength: 0.05%  
Subjects: Healthy males and non-pregnant, non-lactating females  
Additional comments: Refer to the most recent version of the FDA guidance for industry on *Topical Dermatological Corticosteroids: In Vivo Bioequivalence*.<sup>a</sup>
- B. Type of study: Pivotal vasoconstrictor bioequivalence study  
Design: A pivotal bioequivalence study  
Strength: 0.05%  
Subjects: Healthy males and non-pregnant, non-lactating females  
Additional comments: See comments above.

---

**Document History:** Recommended April 2016; Revised August 2024

**Unique Agency Identifier:** PSG\_019968

---

<sup>a</sup> For the most recent version of a guidance, check the FDA guidance website at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents>